histogen
amerimmune
enter
collaborative
development
commercialization
agreement
emricasan
treatment
histogen
receives
ind
approval
fda
initiate
phase
study
emricasan
patients
assess
safety
tolerability
amerimmune
lead
development
efforts
emricasan
phase
study
patients
expected
commence
early
end
san
diego
globe
newswire
histogen
nasdaq
hsto
therapeutics
company
focused
developing
potential
therapeutics
ignite
body
natural
process
repair
maintain
healthy
biological
function
today
announced
entering
collaborative
development
commercialization
agreement
amerimmune
llc
jointly
develop
emricasan
orally
active
caspase
inhibitor
treatment
additionally
histogen
received
investigational
new
drug
ind
approval
united
states
food
drug
administration
fda
initiate
phase
study
emricasan
patients
assess
safety
tolerability
amerimmune
lead
development
efforts
emricasan
selected
clinical
sites
two
major
medical
centers
new
york
city
metropolitan
area
conduct
study
amerimmune
pursuing
funding
order
support
clinical
program
anticipates
initiating
phase
study
early
end
terms
collaboration
histogen
retain
ownership
oversight
emricasan
responsibility
regulatory
filings
maintaining
existing
caspase
inhibitor
patent
portfolio
amerimmune
collaboration
histogen
fund
lead
emricasan
development
efforts
maintain
portfolio
patents
caspase
inhibition
immunotherapy
additionally
amerimmune
granted
option
commercialize
emricasan
certain
conditions
sole
purpose
supporting
future
partnering
transactions
partnering
transaction
emerge
histogen
amerimmune
share
profits
equally
parties
manage
collaboration
joint
development
partnering
committee
governance
structure
since
completing
merger
conatus
pharmaceuticals
second
quarter
evaluating
opportunities
create
value
emricasan
asset
believe
best
accomplished
partnership
amerimmune
potential
treatment
amerimmune
team
brings
strong
caspase
inhibitor
scientific
background
relevant
technologies
treatment
using
caspase
inhibitors
collaboration
said
richard
pascoe
president
ceo
histogen
amerimmune
leading
development
efforts
related
emricasan
histogen
remain
focused
delivering
top
line
data
results
fourth
quarter
phase
trial
androgenic
alopecia
men
evaluating
clinical
pathway
dermal
filler
continuing
progress
program
regeneration
cartilage
knee
concluded
pascoe
delighted
work
collaboration
histogen
explore
potential
role
caspase
inhibition
therapy
reducing
disease
severity
progression
said
dr
oral
alpan
ceo
amerimmune
believe
research
development
efforts
last
decade
enabled
us
make
important
advancements
understanding
compromises
immune
system
encouraged
progress
look
forward
advancing
emricasan
clinic
early
end
concluded
alpan
emricasan
emricasan
orally
active
inhibitor
designed
reduce
activity
enzymes
mediate
inflammation
apoptosis
histogen
believes
reducing
activity
enzymes
caspase
inhibitors
potential
interrupt
progression
variety
diseases
date
emricasan
studied
patients
completed
clinical
trials
across
broad
range
liver
diseases
nash
cirrhosis
patients
multiple
clinical
phase
ii
trials
conducted
conatus
emricasan
demonstrated
rapid
sustained
reductions
elevated
levels
key
biomarkers
inflammation
cell
death
similarly
elevated
biomarkers
also
believed
play
role
severity
progression
histogen
histogen
therapeutics
company
focused
developing
potential
restorative
therapeutics
ignite
body
natural
process
repair
maintain
healthy
biological
function
histogen
innovative
technology
platform
utilizes
cell
conditioned
media
extracellular
matrix
materials
produced
multipotent
cells
histogen
proprietary
reproducible
manufacturing
process
provides
targeted
solutions
across
broad
range
therapeutic
indications
including
hair
growth
dermal
rejuvenation
joint
cartilage
regeneration
spinal
disk
repair
information
please
visit
amerimmune
amerimmune
llc
research
center
immunology
laboratory
strong
focus
identifying
underlying
mechanisms
immune
disorders
amerimmune
mission
bring
relevant
science
data
diagnostic
therapeutic
solutions
diseases
involve
immune
system
amerimmune
llc
spinoff
amerimmune
diagnostics
llc
focused
establishing
network
immunology
labs
across
united
states
amerimmune
diagnostics
clinical
approach
led
development
innovative
therapeutics
technology
upon
amerimmune
founded
pandemic
emerged
early
year
amerimmune
brought
expertise
bear
devastating
disease
amerimmune
privately
held
company
based
fairfax
information
explore
partnering
opportunities
please
visit
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
example
using
statements
discuss
future
operations
ability
successfully
initiate
complete
clinical
trials
obtain
clinical
trial
data
achieve
regulatory
milestones
related
timing
including
related
planned
phase
study
emricasan
treatment
nature
strategy
focus
business
sufficiency
amerimmune
cash
resources
ability
commence
planned
phase
study
emricasan
achieve
value
stockholders
development
commercial
potential
potential
benefits
product
candidates
collaborative
development
commercialization
agreement
amerimmune
collaboration
agreements
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
statements
deal
future
events
based
current
expectations
subject
various
risks
uncertainties
actual
results
performance
achievements
could
differ
materially
described
implied
statements
press
release
including
uncertainties
associated
clinical
development
regulatory
approval
product
candidates
amerimmune
ability
develop
emricasan
treatment
including
complexity
length
studies
required
commercialize
emricasan
potential
delays
commencement
enrollment
completion
clinical
trials
planned
emricasan
phase
study
treatment
uncertainties
associated
amerimmune
pursuit
receipt
capital
advancement
emricasan
including
potential
government
grants
histogen
dependence
collaboration
partner
amerimmune
carry
development
emricasan
potential
delays
timing
regulatory
approval
competition
market
markets
histogen
collaboration
partner
operate
risks
related
business
interruptions
histogen
amerimmune
including
outbreak
coronavirus
could
seriously
harm
respective
financial
conditions
increase
respective
costs
expenses
potential
adverse
reactions
emricasan
market
conditions
foregoing
review
important
factors
could
cause
actual
events
differ
expectations
construed
exhaustive
read
conjunction
statements
included
herein
elsewhere
including
risks
discussed
filings
securities
exchange
commission
except
otherwise
required
law
disclaim
intention
obligation
update
revise
statements
speak
date
hereof
whether
result
new
information
future
events
circumstances
otherwise
contact
susan
knudson
executive
vice
president
cfo
histogen
ir
